Tonsillitis
Return to Library
|
Free Tonsillitis Articles |
|
|
|
|
MiddleBrook Pharmaceuticals Launches MOXATAG™ Website, Announces Early Prescription Data for MOXATAG
2009 MAY 18 - (NewsRx.com) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) has launched a website for MOXATAG (extended-release amoxicillin) Tablets, 775 mg. MOXATAG is the first and only FDA-approved once-daily amoxicillin, and now healthcare professionals and patients have access to a comprehensive online resource for information about treating pharyngitis and tonsillitis, also known as strep throat, with MOXATAG at http://www.moxatag.com. Visitors to the MOXATAG website can learn about the causes, symptoms and treatment of pharyngitis and tonsillitis. A video shows how MiddleBrook’s proprietary drug delivery technology, PULSYS®, prolongs the release and absorption of amoxicillin from MOXATAG to effectively treat bacterial pharyngitis and tonsillitis at a daily dose of 775 mg, which is lower than currently prescribed aminopenicillin therapies. The site also features an informative FAQ section, complete product prescribing information and information for pharmacists. MiddleBrook President and CEO John Thievon said, “MOXATAG is a unique product with no AB-rated generic, and MOXATAG has valuable benefits for patients and prescribers. The MOXATAG website showcases MOXATAG’s attributes and illustrates the compliance-enhancing benefits of once-daily dosing.” Keywords: Amoxicillin, Biotechnology, Drug Delivery, Drugs, FDA, Infectious Disease, Otolaryngology, Pharmaceuticals, Pharyngitis, Regulatory Actions, Strep Throat, Therapy, Tonsillitis, Treatment, U.S. Food and Drug Administration, MiddleBrook Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
